Janssen Pharmaceuticals U.S. transparency report

Janssen Pharmaceuticals U.S. transparency report

Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained commitment to responsible pricing and business practices that put patients first, underscoring the value that Janssen’s medicines provide to patients and the national healthcare system.

Now as always, the report reflects their fundamental beliefs:

  • People should have affordable access to the medicines they need, yet many do not, in part because there is a growing affordability gap between the lower net prices for insurers and the higher costs insurers charge patients.
  • In 2021, the rebates, discounts and fees we provided insurers and others in the healthcare system increased to $33.9 billion. Rebates and discounts helped lower the average net price of our medicines by -2.8%.
    • U.S. government programs already benefit from vigorous private-sector negotiations that result in lower net prices.
  • In 2021, they increased R&D investment to $11.9 billion – 107% more than the cost of our marketing and sales efforts – driving significant medical progress for patients.
  • They continue to advance sustainable solutions that put patients first and strengthen the U.S. healthcare system by combatting healthcare disparities, promoting innovation, and improving affordable access to medicines and vaccines for all.
  • Working together to advance patient-centric policy reforms, they can protect the progress we have made for every patient.

They issue this report each year because open dialogue and partnership are essential to expanding affordable access for patients today and providing greater hope for patients tomorrow. They are committed to being part of sustainable solutions that put patients first.

The full Report and one-page executive summary are available on the Janssen U.S. Transparency Report website.   

CMSC Disclaimer

The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

Elizabeth Porco

Comments are closed.

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last